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harmacopsychiatry and psychotherapy are ben-
eficial for many patients with depression. Evidence-
based and clinical experience collected during the past
decades has allowed the introduction of guidelines and
recommendations from experts in the field1-3 to optimize
antidepressant pharmacotherapy. However, partial
response and nonresponse are frequent,4 despite the
introduction of new psychotropic agents, including
“third-generation antidepressants,”5 and amelioration
and remission rates are still far from optimal. The effi-
cacy of available drugs can be increased, not only by the
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Therapeutic drug monitoring (TDM) of psychotropic drugs such as antidepressants has been widely introduced for opti-
mization of pharmacotherapy in psychiatric patients. The interdisciplinary TDM group of the Arbeitsgemeinschaft für
Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) has worked out consensus guidelines with the aim of pro-
viding psychiatrists and TDM laboratories with a tool to optimize the use of TDM. Five research-based levels of recom-
mendation were defined with regard to routine monitoring of drug plasma concentrations: (i) strongly recommended;
(ii) recommended; (iii) useful; (iv) probably useful; and (v) not recommended. In addition, a list of indications that justify
the use of TDM is presented, eg, control of compliance, lack of clinical response or adverse effects at recommended doses,
drug interactions, pharmacovigilance programs, presence of a genetic particularity concerning drug metabolism, and
children, adolescents, and elderly patients. For some drugs, studies on therapeutic ranges are lacking, but target ranges
for clinically relevant plasma concentrations are presented for most drugs, based on pharmacokinetic studies reported
in the literature. For many antidepressants, a thorough analysis of the literature on studies dealing with the plasma con-
centration–clinical effectiveness relationship allowed inclusion of therapeutic ranges of plasma concentrations. In addi-
tion, recommendations are made with regard to the combination of pharmacogenetic (phenotyping or genotyping) tests
with TDM. Finally, practical instructions are given for the laboratory practitioners and the treating physicians how to use
TDM: preparation of TDM, drug analysis, reporting and interpretation of results, and adequate use of information for
patient treatment. TDM is a complex process that needs optimal interdisciplinary coordination of a procedure implicat-
ing patients, treating physicians, clinical pharmacologists, and clinical laboratory specialists. These consensus guidelines
should be helpful for optimizing TDM of antidepressants.  
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use of augmentation strategies6,7 and other combination
treatments,8,9 but also by analysis of antidepressant drug
concentrations in blood plasma.10 Recently, a group 
of psychiatrists, clinical pharmacologists, biochemists,
and clinical chemists, all members of the AGNP
(Arbeitsgemeinschaft für Neuropsychopharmakologie
und Pharmakopsychiatrie; www.agnp.de), worked out
consensus guidelines for therapeutic drug monitoring
(TDM) in psychiatry, after they had compiled informa-
tion from the literature.11 These guidelines were mainly
based on the hypothesis that some inadequate or insuf-
ficient treatments of psychiatric patients can be
explained by the fact that psychotropic drugs not only
differ in their pharmacological profile, but also in their
metabolism and pharmacokinetics in the individual
patient. Treatment should therefore be adapted accord-
ing to this situation by using TDM and pharmacogenetic
tests.This combined strategy takes into consideration the
fact that the fate of the drug depends on both environ-
mental (diet, smoking habits, comorbidities, and comed-
ications) and genetic factors.
Pioneering work in this field was mainly carried out in
Sweden, where the first study on the plasma concentra-
tion–clinical effectiveness relationship of an antidepres-
sant (nortriptyline)12 was performed. This was an out-
standing demonstration of the usefulness of the
combination of TDM and pharmacogenetic tests (CYP
2D6) in a pharmacovigilance case situation.13 Over the
past 20 years, TDM for antidepressants has been widely
introduced, but consensus guidelines published to date,
or other state-of-the-art reports on the use of TDM for
antidepressants concentrated primarily on tricyclic
drugs.14-17 There is an increasing trend to recommend
TDM in combination with pharmacogenetic tests.18,19
Aims of the consensus document
The present consensus guidelines were elaborated to
assist psychiatrists, laboratory practitioners, and heads
of laboratories involved in psychopharmacotherapy to
optimise the use of TDM. Here we focus on antidepres-
sants,* and give recommendations on how to use TDM
and genotyping/phenotyping procedures.
Pharmacokinetics, metabolism, and 
pharmacogenetics of antidepressants
Antidepressants share many common features, such as
high lipophilicity, a molecular weight between 200 and
500, and basicity. We therefore present a general sum-
mary of their pharmacokinetic properties  in Table I,20-26
though numerous compounds constitute exceptions:
citalopram is known for its high bioavailability (about
90%) and relatively low binding to plasma proteins
(80%); venlafaxine, trazodone, tranylcypromine, and
moclobemide display a short (about 2-10 h) and fluoxe-
tine a long plasma half-life (3-15 days, taking into account
its active metabolite). It should also be considered that
many antidepressants, such as venlafaxine, citalopram,
*This review takes into consideration antidepressant agents
currently available in Switzerland and Germany, and therefore
does not claim to be exhaustive.
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Selected abbreviations and acronyms
CYP cytochrome P-450
GC gas chromatography
HPLC high-performance liquid chromatography
LOD limit of detection
LOQ limit of quantification
PM poor metabolizer
SSRI selective serotonin reuptake inhibitor
TDM therapeutic drug monitoring
UM ultrarapid metabolizer
and mirtazapine, are used as racemic compounds, the
enantiomers of which differ in their pharmacological,
metabolic, and pharmacokinetic properties.27,28
Most antidepressants undergo phase I metabolism by oxi-
dation, such as aromatic ring and aliphatic hydroxylation,
N- and O-dealkylation, N- and O-oxidation to N-oxides,
carbonyl reduction to secondary alcohols, and S-oxidation
to sulfoxides or sulfones, which results in an increase in
polarity.29 The introduction of a functional group (eg, a
hydroxy group) or the presence of a tertiary amine group
may enable a phase II metabolic step, typically a glu-
curonidation.30-32 Metabolism occurs mainly in the liver and
in the intestinal mucosa. It may be age-dependent, and
vary as a consequence of the influence of environmental
factors, such as somatic diseases, comedication, food, and
smoking.TDM should include the assay of active metabo-
lites33-35 (eg, clomipramine [norclomipramine] and fluoxe-
tine [norfluoxetine]), but the parent compound/inactive
metabolite ratio may be helpful to evaluate the metabolic
state or compliance of the patient.
Considerable and clinically relevant knowledge has been
acquired during the past 30 years on the important role of
cytochrome P-450 (CYP) isozymes, CYP 1A2, CYP 2D6,
CYP 2C9, CYP 2C19, and CYP 3A4/5, in the biotransfor-
mation of antidepressants.36-42 The genetically determined
polymorphism of CYP 2D6 is of high clinical relevance for
antidepressants, which are substrates of this isozyme,
including tricyclic antidepressants, some selective serotonin
reuptake inhibitors (SSRIs) (eg, paroxetine and fluoxe-
tine), and “third-generation” antidepressants (eg, ven-
lafaxine and mirtazapine). About 5% to 8% and 1% to
7% of the Caucasian population are considered as poor
metabolizers (PMs) or ultrarapid metabolizers (UMs),
respectively (Table I).22,43,44 In Caucasians, there is a lower
proportion (3%-5%) of PMs of CYP 2C19, which is fre-
quently involved in N-demethylation of tertiary amines
(amitriptyline and citalopram). CYP 3A4/5 shows wide
interindividual variability in its activity. CYP 3A5 is
expressed in only one-third of the Caucasian population.45
As regards CYP 1A2, only its inducibility (eg, by tobacco
smoke) is genetically polymorphic.46,47 Clinically, a PM sta-
tus may represent a higher risk for adverse effects in
patients treated with antidepressants known to be sub-
strates of the deficient enzyme, while UMs undergo a
higher risk for nonresponse, due to subtherapeutic plasma
concentrations.39,48-53 The clinical relevance of the genetic
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Table I. General pharmacokinetic properties (absorption, distribution, metabolism, and elimination [ADME]) of antidepressants.11,20
Pharmacokinetic phase Characteristics
Absorption A Good absorption from gastrointestinal tract
Maximum plasma concentration within a short time after administration (tmax of about 0.5 to 4 h)
Distribution D High distribution volume
Fast distribution from plasma to the central nervous system
10 to 40 times higher levels in brain than in blood
Possible regulation of transport intestine–blood and blood–brain by transport proteins (P-glycoprotein)
Low plasma concentrations in steady-state conditions (trough levels: 0.5-500 ng/mL)
High plasma protein binding (90%-99%)
Metabolism M Metabolism: a prerequisite for excretion
High first-pass metabolism (systemic availability: 10%-70%)
Main metabolic enzyme systems: cytochrome P-450, UDP-glucuronosyltransferases
Genetic polymorphisms for some enzymes (extensive, intermediate, poor, and ultrarapid metabolizers)
Inducibility of some enzymes by drugs or other xenobiotics
Generally formation of active, but more polar metabolites
Occurrence and relevance of metabolism in brain doubtful
Important effect of hepatic insufficiency on hepatic elimination
High risk for inhibition of drug metabolism by comedication, inhibitors of cytochrome P-450
Elimination E Low renal excretion
Small effect of renal insufficiency on plasma kinetics of drug and its metabolites
Slow elimination from plasma (half-life 12-36 h), mainly by hepatic metabolism
ADME Linear pharmacokinetics at clinically relevant doses
polymorphisms of UDP-glucuronosyltransferases in phar-
macopsychiatry is not clear.30,54
Genotyping, which represents a “trait marker,” is readily
available and clinically recommended for CYP 1A2,
CYP 2C9, CYP 2C19, CYP 2D6, and CYP 3A4/5; phe-
notyping, used as a “state-marker,” may be performed for
the same enzymes. The result of genotyping is not influ-
enced by environmental factors and has life-long valid-
ity. Phenotyping requires the administration of drugs and
is therefore a more invasive procedure. Therefore, indi-
cations for phenotyping and genotyping may differ.
As mentioned in Table I, transport proteins such as 
P-glycoprotein in the intestinal mucosa and in the
blood–brain barrier may be implicated in the regulation
of the availability of antidepressants for the brain, but
there is still a lack of clinical data.55-57
Relationships between drug doses, plasma
concentrations, and clinical variables
TDM is based on the hypothesis assumption that there
is a well-defined relationship between the drug plasma
concentration and its clinical effects (therapeutic effect,
adverse effects, and toxicity). However, while such a
relationship is generally well admitted for lithium and
for the tricyclic antidepressants nortriptyline, amitripty-
line, desipramine, and imipramine, inconsistent results
were obtained in studies on other tricyclic or similarly
structured antidepressants, SSRIs, and other recently
introduced antidepressants.20,58-62 Interestingly, systematic
reviews and meta-analyses14,59 that were based on ade-
quately designed studies yielded evidence of a relation-
ship between clinical variables and plasma concentra-
tion for some tricyclic drugs.This suggests that numerous
studies were poorly designed methodologically in order
to demonstrate an evident relationship between con-
centration and effects or side effects. Recently, Ulrich
and Läuter60 defined criteria for quality assessment of
TDM studies, which include the use of valid chemical
and analytical methods, adequate psychopathology rat-
ing scales, appropriate selection criteria for patients (eg,
exclusion of known nonresponders), and reporting of
comedication.
Analytical procedures
Plasma or serum samples are generally used for TDM.
Concentrations of antidepressants are low, most often in
the nmol/L (ng/mL) range. Therefore, highly sensitive
and selective analytical methods are needed for accurate
and precise quantification.63-66
Most laboratories use now gas chromatography (GC) or
high-performance liquid chromatography (HPLC) for
the assay of antidepressants for TDM purposes. For GC,
the most recommended detection systems are mass
spectrometry (GC-MS) or nitrogen phosphor detectors
(GC-NPD). Ultraviolet (UV) detectors, fluorescence
detectors, and mass spectrometry (LC-MS), in increas-
ing order, are useful for a selective and sensitive drug
assay. Clearly, the need for sample preparation before
chromatographic separation represents a time-consum-
ing step, and this procedure also implies a limited sam-
ple throughput, despite the availability of automated
sample preparation prior to GC or HPLC.67 Direct injec-
tion (“column switching HPLC”) of plasma or serum
into the HPLC system is now available for a number of
antidepressants.68-70 LC-MS and LC-MS-MS (tandem
mass spectrometry) will increasingly be the method of
choice, as it may be applied to almost any psychotropic
drug including metabolites, while GC-MS is applicable
only for volatile compounds.
Economic aspects of TDM in psychiatry
TDM for a single psychoactive drug, including a metabo-
lite, costs between 20 and 80 €, which includes costs for
staff, instrumentation, chemicals, and other materials. In
some countries, analyses may be billed according to the
analytical technique used (higher rates for mass spec-
trometric quantification).
A proof of cost-effectiveness has been provided for only
a few antidepressants.71,72 However, additional studies are
required.They should be designed to take account of the
complexity of the TDM process (Figure 1). For example,
a recent prospective study carried out under naturalistic
conditions showed that dose adjustment by the treating
physician was frequently inappropriate, in that he or she
neglected the results of the laboratory assays.73
Preliminary data suggest that phenotyping or genotyp-
ing of patients may help decrease the cost of their treat-
ment with substrates of CYP 2D6.74 The costs of treating
patients who are either UMs or PMs (CYP 2D6) are
seemingly thousands of US dollars per year higher than
those for extensive metabolizers (EMs).75 However, the
tools to assess the cost-effectiveness of pharmacogenetic
tests are still insufficiently developed.76
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Consensus
TDM should be limited to situations where it may be
expected that the result will help to solve a therapeutic
problem. There are many indications for using TDM
(Table II) in antidepressant pharmacotherapy, such as
suspicion of noncompliance or intoxication. In pharma-
covigilance programs,TDM may be considered as a valid
indication for all drugs and groups of patients. To rec-
ommend TDM as routine monitoring, it must be proven
that TDM is of value. Five levels of recommendation for
TDM were defined, which range from “strongly recom-
mended” to “not recommended.” In a second step, a rec-
ommendation tailored to the individual drug was
defined.
Levels of recommendations to use TDM as routine 
monitoring
The therapeutic strategy will only be improved by the
use of TDM, if the already mentioned criteria are ful-
filled.60 There is sufficient evidence that TDM can be
useful for patients treated with antidepressants, as con-
cluded by the authors of this consensus guideline, after
a careful examination of the literature: (i) guidelines; (ii)
meta-analyses; (iii) prospective studies on the clinical
effectiveness of drugs in which drug plasma concentra-
tions were reported; and (iv) pharmacokinetic studies.
However, the latter often do not allow definition of a
therapeutic plasma concentration range, in the absence
of clinical data. Five levels of recommendation to use
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Figure 1. Summary of the therapeutic drug monitoring (TDM) process for optimization of the pharmacotherpy of psychiatric patients. Routine mon-
itoring should be restricted to psychoactive drugs with established therapeutic ranges and who levels of recommendation to use TDM are
at least 2 (Table IV). Specific requests may be useful for any psychoactive drug and many indications (Table I), even without well-estab-
lished therapeutic ranges.11
Blood sample collection
Laboratory measurements
Communication of results
Therapeutic management
Optimization of drug treatment
Routine monitoring Specific indication
Steady state at the time of minimal drug concentration (trough level)
Complete request form (demographic data, diagnosis, medication, comedication, therapeutic effect, and side effects)
Use of validated methods (linearity, accuracy, precision, sensitivity, specificity)
Internal and external quality control management
Reporting of drug concentration including unit and range of target concentration
Interpretation related to the patient's state
Change in dose, cessation of drug, change in comedication, discussion of the results with the patient 
(eg, compliance, safety), pharmacogenetic monitoring, no intervention
Consideration of the patient's clinical state Consideration of drug concentration in plasma
and interpretation of results
Dose titration after start or change of medication, 
relapse prevention
Lack of response, insufficient response, side effects at 
therapeutic doses, potential drug interaction or other 
specific indications (Table I)
TDM as routine monitoring were defined as follows, as
reported earlier.10
1. Strongly recommended
• Established therapeutic range 
• Level of evidence: Controlled clinical trials have shown
benefit of TDM; reports on toxic effects at “suprather-
apeutic” plasma concentrations.
• Clinical consequences: At therapeutic plasma concen-
trations highest probability of response; at “subthera-
peutic” plasma concentrations response rate similar to
placebo; at plasma concentrations higher than thera-
peutic concentrations increasing risk of adverse effects.
2. Recommended
• Suggested therapeutic ranges obtained from plasma
concentrations at therapeutically effective doses (fixed
dose studies).
• Level of evidence:At least one well-designed prospective
study with well-defined outcome criteria reports intoxi-
cations at “supratherapeutic” plasma concentrations.
• Clinical consequences:TDM most probably will optimize
response in nonresponders: at “subtherapeutic” plasma
concentrations risk of poor response; at “suprathera-
peutic” plasma concentrations risk of adverse effects
and/or decreased response.
3. Useful
• Suggested therapeutic ranges are plasma concentra-
tions at effective doses obtained from steady-state
pharmacokinetic studies.
• Level of evidence: Clinical data from retrospective
analysis of TDM data; single case reports; or nonsys-
tematic clinical experience.
• Clinical consequences:TDM useful to control whether
plasma concentrations are plausible for a given dose;
optimizing of clinical response in nonresponders who
display low concentrations is possible.
4. Probably useful
• Suggested therapeutic ranges from steady-state phar-
macokinetic studies at therapeutically effective doses.
• Level of evidence: Valid clinical data so far lacking or
inconsistent results.
• Clinical consequences:TDM useful to control whether
plasma concentrations are plausible for a given dose.
5. Not recommended
• Unique pharmacology of the drug, eg, irreversible
blockade of an enzyme or flexible dosing according to
clinical symptoms.
• Level of evidence: Textbook knowledge, basic phar-
macology.
• Clinical consequences: TDM should not be used.
Drug-specific TDM recommendations
The knowledge of plasma concentrations ranges observed
after treatment of subjects at well-defined doses of the
antidepressant (Table III) may efficiently help the clinician
in some of the situations listed in Table II: suspicion of
noncompliance, drug interactions, problems occurring after
switching from an original preparation to a generic form
(and vice versa), or presence of a pharmacogenetic PM or
UM status. The information available in Table III is also
helpful in situations where the levels of recommendations
3 and 4 apply (ie,TDM useful or probably useful).
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Table II. General indications for therapeutic drug monitoring (TDM) of
antidepressants.11
Suspected noncompliance
Drugs, for which TDM is mandatory for safety reasons (eg, lithium)
Lack of clinical response, or insufficient response, even if dose is 
considered as adequate
Adverse effects, despite the use of generally recommended doses
Suspected drug interactions
TDM in pharmacovigilance programs
Combination treatment with a drug known for its interaction 
potential, in situations of comorbidities, “augmentation,” etc
Relapse prevention in long-term treatments, prophylactic treat-
ments
Recurrence despite good compliance and adequate doses
Presence of a genetic particularity concerning the drug metabolism
(genetic deficiency, gene multiplication)
Children and adolescents
Elderly patients (>65 years)
Patients with pharmacokinetically relevant comorbidities (hepatic 
or renal insufficiency, cardiovascular disease)
Forensic psychiatry
Problems occurring after switching from an original preparation to 
a generic form (and vice versa)
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Table III. Dose-related steady-state plasma concentrations of antidepressants.11 Generally, arithmetic means ± standarad deviations are given; numbers
in parentheses indicate ranges. md, median value; gm, geometric mean; m, males; f, females. *Extensive metabolizers (CYP 2D6). †Doxepin
+ desmethyldoxepin. ‡Patients were treated with 20 mg/day citalopram, and S-citalopram and its metabolite were measured. §Nonsmokers. 
||Smokers. ¶Concentrations given in ng.kg/mL.mg, in extensive metabolizers (CYP 2D6). #Concentrations show very little differences when given
50 mg/day tid.
Antidepressant Active  Dose-related steady-state plasma concentrations*
metabolite Dose Parent compound Metabolite References
(or metabolite (mg/day) (ng/mL) (ng/mL)
recommended
for TDM)
Amitriptyline Nortriptyline 150 102±59 (34-278) 85±60 (16-326) Baumann et al,77 1986
150 122±62 84±48 Jungkunz and Kuss,78 1980
150 76±30 84±38 Breyer-Pfaff et al,79 1982
150 100±41 71±38 Breyer-Pfaff et al,80 1982
200 146±21 (sem) 129±23 (sem) Kupfer et al,81 1977
Citalopram Demethylcitalopram 40 86±38 35±11 Baumann et al,82 1996
40 iv 70±23 30±12 Baumann et al,83 1998
Clomipramine Demethylclomipramine 75 bid 63 md (22-230)* 148 md ( 51-331)* Kramer Nielsen et al,84 1992
50 24 md (5-69)* 15 md (6-78)* DUAG,85 1999
75 38 md (9-78)* 43 md (5-102)* DUAG,85 1999
125 83 md (31-224)* 105 md (41-335)* DUAG,85 1999
200 202 md (50-340)* 283 md (138-446)* DUAG,85 1999
100 iv 122±73 145±118 Müller-Oerlinghausen and 
Fähndrich,86 1985
150 74-310 69-267 Burch et al,87 1982
Desipramine 200 173 (28-882) Friedel et al,88 1979
186±24 188±152 Amsterdam et al,89 1985
75-250 16-502 Nelson et al,90 1985
Dothiepine Dothiepine-SO 150 95±67 323±191 Maguire et al,91 1982
Northiaden 150 16±12 Maguire et al,91 1982
Dothiepine-SO 3.22±0.99 mg/kg 67 (4-258) 352 (45-953) Ilett et al,92 1993
Northiaden 3.22±0.99 mg/kg 37 (0-230) Ilett et al,92 1993
Doxepin (DOX) Demethyldoxepin (DDOX) 250 484±251 nmol/L† Adler et al,93 1997
Demethyldoxepin 250 130±113 132±94 Deuschle et al,94 1997
trans-Demethyldoxepin 250 72±60 Deuschle et al,94 1997
cis-Demethyldoxepin 250 60±45 Deuschle et al,94 1997
143±30 89±75† Leucht et al,95 2001
Escitalopram‡ S-Demethylcitalopram 10‡ 27±14 14±5 Bondolfi et al,96 1996
10‡ 28±9 11±3 Bondolfi et al,97 2000 
Fluoxetine Norfluoxetine 20 80 (9-265) md 126 (30-300) md Lundmark et al,98 2001
40 195 (40-496) md 221 (20-449) md
20 97±51 128±49 Amsterdam et al,99 1997
Fluvoxamine 100 90±29 (f) Härtter et al,100 1998
100 59±22 (m) Härtter et al,100 1998
200 274±73 (f) Härtter et al,100 1998
200 237±90 (m) Härtter et al,100 1998
229±47 142±108 (20-417) Kasper et al,101 1993
200 162±144 (13-833) Gerstenberg et al,102 2003
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Table III. Continued.
Antidepressant Active  Dose-related steady-state plasma concentrations*
metabolite Dose Parent compound Metabolite References
(or metabolite (mg/day) (ng/mL) (ng/mL)
recommended
for TDM)
Imipramine Desipramine 225 (6-268) (18-496) Reisby et al,103 1977
Maprotiline (Desmethylmaprotiline) 150 116±47 Gabris et al,104 1985
236±32 202±134 (12-428) Kasper et al,101 1993
Mianserin Demethylmianserin 30 22 (12-48) 9 (3-24) Otani et al,105 1991
(MIA) (DMIA) 30 14 (6-37) (S-MIA) Mihara et al,106 1997
30 9 (4-18) (R-MIA) Mihara et al,106 1997
60 37±19 (14-67) (S-MIA) 10±5 (6-23) (S-DMIA) Eap et al,107 1999
60 19±11 (10-51) (R-MIA) 21±15 (10-52) (R-DMIA) Eap et al,107 1999
Mirtazapine (Demethylmirtazapine) 15 7.3±3.2 Timmer et al,108 1995
30 18±7 Timmer et al,108 1995
45 28±12 Timmer et al,108 1995
60 38±16 Timmer et al,108 1995
70 46±16 Timmer et al,108 1995
Moclobemide 100 tid 216±55 Schoerlin et al,109 1987
Nortriptyline 150 141±48 (48-238)
75-225 90±40 (32-164) Asberg et al,12 1971
Paroxetine 30 36.3 (1.7-60.8) Lundmark et al,110 1989
30 27 md (12-45)* Sindrup et al,111 1992
30 36 (9-70) Kaye et al,112 1989
Reboxetine 4 50±20 Pellizzoni et al,113 1996
Sertraline (Norsertraline) 50 12±17 gm (3-134) 30±24 gm (7-143) Lundmark et al,114 2000
100 19±18 gm (3-109) 45±35 gm (10-273) Lundmark et al,114 2000
150 31±29 gm (8-145) 65±47 gm (7-138) Lundmark et al,114 2000
200 29±18 gm (9-82) 87±43 gm (40-189) Lundmark et al,114 2000
50 12±8 (4-32) Axelson et al,115 2002
Trazodone m-Chlorophenylpiperazine 150 624 (271-1062) 65 (34-108) Otani et al,116 1998
150 680±257§ 65±21§ Mihara et al,117 2001
150 541±277|| 56±21|| Mihara et al,117 2001
Trimipramine Desmethyltrimipramine 200 277±67 169±51 Cournoyer et al,118 1987
(TRI) (DTRI) 21±11 (7-47) (L-TRI)¶ 7±6 (1-23) (L-DTRI)¶ Eap et al,119 2000
18±6 (8-32) (D-TRI)¶ 10±7 (2-29) (D-DTRI)¶ Eap et al,119 2000
Venlafaxine O-Demethylvenlafaxine 75 bid# 56±31 194±75 Troy et al,120 1995
75 75±93 (5-427) 116±65 (16-260) Reis et al,121 2002
150 109±232 (4-1903) 186±94 (16-411) Reis et al,121 2002
225 178±283 (9-1421) 232±132 (63-736) Reis et al,121 2002
300 155±109 (21-438) 249±121 (104-516) Reis et al,121 2002
Viloxazine 300 1200 (ca 400-1600) Müller-Oerlinghausen and 
Ruether,122 1979
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Table IV. Recommended target plasma concentration ranges for antidepressant drugs and levels of recommendation for routine monitoring.11
Therapeutic ranges indicate trough concentrations of drugs in serum or plasma of patients under steady-state medication. Level of rec-
ommendation: 1. Strongly recommended (for lithium TDM should be a standard of care): established therapeutic range; 2.
Recommended: suggested therapeutic ranges obtained from plasma concentrations at therapeutically effective doses (fixed dose stud-
ies); 3. Useful: suggested therapeutic ranges are plasma concentrations at therapeutically effective doses obtained from steady-state
pharmacokinetic studies; 4. Probably useful: suggested therapeutic ranges from steady-state pharmacokinetic studies at therapeuti-
cally effective doses; 5. Not recommended. SPC, Summary of Product Characteristics.
Drug and active  Recommended  Level of References for reports on Reference for reports on
metabolite for therapeutic range recommendation therapeutic ranges intoxications
antidepressants (consensus)
Amitriptyline plus 80-200 ng/mL 1 Ulrich and Läuter,60 2002 Preskorn and Jerkovich,124 1990
nortriptyline Pedersen et al,123 1982
Citalopram 30-130 ng/mL 3 Bjerkenstedt et al,125 1985 Jonasson and Saldeen,127 2002
Leinonen et al,126 1996
Clomipramine plus 175-450 ng/mL 1 DUAG,85 1999 McIntyre et al,130 1994
norclomipramine Gex-Fabry et al,128 1999
Mavissakalian et al,129 1990
Desipramine 100-300 ng/mL 2 Perry et al,59 1994 Preskorn and Jerkovich,124 1990
Pedersen et al,123 1982
Doxepin plus nordoxepin 50-150 ng/mL 3 Leucht et al,95 2001 Preskorn and Fast,132 1992
Rodriguez de la Torre et al,131 2001
Escitalopram 15-80 ng/mL 4 SPC
Fluoxetine plus norfluoxetine 120-300 ng/mL 3 Lundmark et al,98 2001
Amsterdam et al,99 1997
Fluvoxamine 150-300 ng/mL 4 Gerstenberg et al,102 2003 Kasper et al,101 1993
Goodnick,133 1994
Imipramine plus 175-300 ng/mL 1 Perry et al,59 1994 Pedersen et al,123 1982
desipramine
Maprotilin 125-200 ng/mL 3 SPC, Kasper et al,101 1993 Pedersen et al,123 1982
Mianserin 15-70 ng/mL 3 Montgomery et al,134 1978 Isacsson et al,135 1997
Mirtazapine 40-80 ng/mL 3 Timmer et al,136 2000 Velazquez et al,137 2001
Moclobemide 300-1000 ng/mL 4 Fritze et al,138 1989 Hernandez et al,140 1995
Gex-Fabry et al,139 1995
Nortriptyline 70-170 ng/mL 1 Perry et al,12 1994 Åsberg et al,141 1970
Åsberg et al,59 1971
Paroxetine 70-120 ng/mL 3 Lundmark et al,114 2000
Tasker et al,142 1989
Reboxetine 10-100 ng/mL 4 Ohman et al,143 2001
Sertraline 10-50 ng/mL 3 Lundmark et al,114 2000 Milner et al,144 1998
Tranylcypromine 0-50 ng/mL 5 Burke and Preskorn,145 1999 Iwersen and Schmoldt,146 1996
Trazodone 650-1500 ng/mL 3 Monteleone et al,147 1989
Goeringer et al,148 2000
Trimipramine 150-350 ng/mL 3 Cournoyer et al,118 1987
Isaccson et al,135 1997
Venlafaxine plus 195-400 ng/mL 2 Veefkind et al,149 2000
O-desmethylvenlafaxine Levine et al,150 1996
Viloxazine 20-500 ng/mL 3 Norman et al,151 1980 Falcy et al,153 1983
Altamura et al,152 1986
However, the data presented in Table III are insufficient
to allow levels of recommendations 1 or 2, as it does not
include studies on the plasma concentration–clinical
effectiveness relationship. Therefore, the literature had
to be reexamined to define which antidepressants may
get a level 3 or 4 of recommendation for their monitor-
ing. By consensus, a therapeutic range was then also
defined for their “main” (= depression) indication (Table
IV), as data for other indications (eg, anxiety disorders)
are most often lacking, and some studies suggest that
optimal ranges may differ, depending on the pathology.154
Antidepressants differ widely in their chemical structure
and their pharmacological activity, even though most are
serotonergic and/or noradrenergic. “Therapeutic win-
dows” have been defined for most tricyclic antidepres-
sants, and TDM is recommended to avoid intoxications,
which may be lethal (Table IV).
As regards more recently introduced antidepressants, a
clearcut plasma level–clinical effectiveness relationship
was not demonstrated for tetracyclic antidepressants
(maprotiline, mianserin, or mirtazapine), trazodone, rebox-
etine, the monoamine oxidase inhibitors moclobemide and
tranylcypromine,133 and SSRIs.21,155,156 However, TDM of
SSRIs was shown to be cost-effective, as it helps to use
minimum effective doses.114 Therefore, data on the plasma
concentrations at therapeutic doses may be clinically use-
ful for these drugs (Table III), in situations of noncompli-
ance, nonresponse, adverse effects, or intoxication.
Specific indications for TDM in psychiatry
Therapeutic windows should be interpreted in the con-
text of the clinical situation, before the decision to
change treatment strategy is taken. As an example, low
levels may be sufficient for the antidepressant doxepin,
if it is used to obtain sedation.95
Interestingly, despite the increasing use of generics, there
are few data available that demonstrate unambiguously
the occurrence of pharmacokinetic problems after switch-
ing from an original preparation to a generic form (and
vice versa).157-160 TDM is a general indication for the admin-
istration of psychotropic drugs in children and adolescents
because psychopharmacotherapy of children and adoles-
cents differs from that of adults (Gerlach et al, in press):
(i) There are differences in the pharmacokinetic behavior
of drugs used in dependence on the stage of development;
it is therefore not appropriate to use dosages recom-
mended for adults. (ii) Many drugs are not approved for
use in children and adolescents; the consequence is that
the criteria for efficacy and safety, guaranteed for the use
in adults, are not given for administration in children and
adolescents. There is, however, a need to carry out stan-
dardized studies to find therapeutic ranges of plasma con-
centrations for children and adolescents.
In these patients, but also in elderly subjects, TDM may
help distinguish between pharmacokinetic and pharma-
codynamic factors in the occurrence of adverse effects.
Consequently, TDM also represents a useful tool in sit-
uations of pharmacovigilance programs.
Antidepressants should be monitored in the blood of
pregnant or lactating women in order to minimize drug
exposure of the fetus or newborn infant.161-165
Investigations on the “therapeutic window” of patients
should not only be included in phase IV studies. If possi-
ble, they should also be carried out in phase III studies, in
relationship with clinical ratings, in order to propose TDM
with the introduction of the new drug.As stated in the doc-
ument published by the European Agency for the
Evaluation of Medicinal Products,166 an established con-
centration–response relationship is the basis to forecast
the chance of toxicity due to pharmacokinetic differences,
drug–disease, or drug–drug interactions.
Pharmacogenetic tests in addition to TDM
There is increasing evidence for an advantage to combine
pharmacogenetic tests with TDM.18,39,44,167 However, phar-
macogenetic tests alone have limited value, as environ-
mental factors also regulate drug metabolism.168 Some of the
most important indications for phenotyping and/or geno-
typing (in combination with TDM) are the following.51,168
• The metabolism of the medication (or its active
metabolite) is governed to a significant extent by the
enzyme, which is considered to be phenotyped or
genotyped.
• The patient is treated with a substrate whose metabo-
lism shows a wide interindividual variability, as demon-
strated by TDM.
• A drug is characterized by a low therapeutic index, ie,
risk of toxicity in the case of a genetically impaired
metabolism or, on the other hand, risk of nonresponse
due to an ultrarapid metabolism and the inability to
reach therapeutic drug levels.
• The patient presents unusual plasma concentrations of
the drug or its metabolite(s), and genetic factors are
suspected to be responsible.
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• The patient suffers from a chronic illness, which
requires life-long treatment.
As outlined above, both phenotyping and genotyping
are recommended in some circumstances, as a “trait-
marker” and a “state-marker.” Currently, data obtained
by TDM represent a “state-marker.”
Practical aspects of TDM
Previous studies suggest that the “compliance” of the
treating physician needs to be improved, as many
requests or indications for TDM were inappropriate.169
Moreover, clinicians frequently do not follow the rec-
ommendations given by the laboratory to adjust the
treatment.73 Therefore, some practical recommendations
are summarized (see reference 11 for a comprehensive
presentation) for the optimal use of TDM, as illustrated
in Figure 1.
Recommendations for the treating physician
Preparation of TDM
Some patients may particularly benefit from TDM: an
antidepressant drug should then be recommended for
which TDM is available, either to minimize adverse
effects or optimize its clinical efficacy. A well-defined
“therapeutic window” for this drug (Table IV) or at least
known plasma concentration ranges for clinical doses
(Table II) should be available.
Blood should be collected for TDM in steady-state con-
ditions, ie, at least 5 drug half-lives after changes in dose
and during the terminal β-elimination phase. Generally,
the appropriate sampling time for most antidepressants
(except for fluoxetine) is 1 week after stable daily dos-
ing and immediately before ingestion of the morning
dose, ie, about 12 to 16 h (or 24 h if the drug is given
once daily) after the last medication. It should be con-
sidered that both after a modification of the dose and
after prescription of a comedication, which may inhibit
or enhance the metabolism of the drug to be measured,
steady-state conditions are reached again only after a
few days. TDM should then be delayed, in case unex-
pected side effects are observed.
Most antidepressants are stable in serum or plasma for at
least 24 h170 and can therefore be sent to the laboratory at
room temperature. It is mandatory to consider technical
recommendations given by the laboratory: choice of anti-
coagulant (plasma, serum), sample volume and its labeling,
conditions for mailing, influence of light, and temperature.
Information on comedication may help the laboratory
to avoid analytical problems (interferences with other
drugs). It is strongly recommended to fill out the request
forms adequately and completely (diagnosis, comor-
bidities, comedications, treatment duration, doses, sex
and age of the patient, and reasons for the request), in
order to allow interpretation of the result by clinical
pharmacologists. Some of these data may also represent
important information for the laboratory to judge plau-
sibility of the result.
Critical appreciation of the results
A pharmacological treatment should be guided by
sound clinical judgment. TDM has to be considered as
an additional and useful tool for optimizing therapy.
Analytical methods used in the laboratories may differ
in their quality.The physician should be aware that some
drug levels are not accurately measured, even though
most laboratories have introduced a program to mea-
sure quality. Indeed, worldwide external quality-control
programs show considerable variability between labo-
ratories in the results of analysis of control samples.The
physician may obtain discrepant results when a drug was
monitored several times in a patient, but analyzed in dif-
ferent laboratories. When comparisons of TDM values
obtained from different laboratories are carried out, the
clinician should take into account the units (ng/mL,
µg/L, µmol/L, nmol/L) in which the results of the analy-
sis are expressed.
Low plasma drug concentrations suggest either irregu-
lar intake of the drug or ultrarapid metabolism, and in
this situation, a pharmacogenetic test may be indicated.
In the first case, TDM should be repeated in order to
verify compliance. These examples show that it may be
advantageous for the clinician to collaborate with a
TDM laboratory that offers pharmacological consulta-
tion.
TDM interpretation and treatment of patients
A TDM result represents a guide to adjust the treatment
of the individual patient, but expert interpretation and
adequate use of this pharmacokinetic data are manda-
tory for an optimal clinical benefit. Reporting of results
and inclusion of dose recommendations and other com-
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ments by the laboratory must be guided by the best
available evidence. However, the laboratory has only
limited knowledge of the clinical context. The physician
should also take into consideration whether the “refer-
ence plasma concentrations range” reflects only “drug
plasma concentrations at clinically relevant doses”
(Table III) or whether they are “therapeutic ranges”
(Table IV). Information on the level of recommendation
for TDM of the particular drug may also help evaluate
the clinical significance of the result (Table IV). If the
plasma concentration of the drug is within the thera-
peutic range, an adaptation of the dose is, of course, only
recommended when clinical reasons, such as adverse
effects or nonresponse, clearly justify such a decision.
When the advice given on the TDM report is not fol-
lowed, the reason for such a decision should be carefully
documented.
Recommendations for the laboratory
Analytical procedures
The concentrations of antidepressants are generally low,
in the ng/mL range, and many patients are comedicated
with various, potentially interfering drugs. The methods
should be adapted to this situation by precision (coeffi-
cient of variation <15%), accurateness (deviation from
nominal value <15%), and robustness.5 Each assay needs
to be validated, documented, and regularly assessed for
linearity, selectivity, accuracy, precision, recovery, and
sensitivity (limits of detection [LOD] and quantification
[LOQ]). Internal and external quality control proce-
dures are mandatory to ensure maximal quality of TDM.
If quality controls are outside the expected range, the
reason underlying the outlier needs to be clarified and
documented.64-66
Where indicated the laboratory should analyze both the
drug and its active metabolite(s) (Tables II and III).
Moreover, the analysis of (active and inactive) metabo-
lites represents an additional tool to verify compliance
of patients.
Reporting of results 
In addition to the result, the appropriate target range
should be communicated to the physician (Tables II and
III), using, of course, the same units (either mass or
molar units). The LOD, or preferentially the LOQ,
should be indicated in situations when plasma drug con-
centrations are below these values.The results should be
available for clinical interpretation within a clinically
meaningful time, especially in case of suspected intoxi-
cations. An interpretation and clinical and pharmaco-
logical advice should be provided with every report.
Therefore, it is advantageous for the clinician to choose
a laboratory that offers this service.
Plasma concentrations must be interpreted in the light
of sound clinical judgment. Most frequently, recommen-
dations on dose changes are given, and in a situation of
drug concentrations above the recommended range,
rapidity of communication may enhance successful
intervention in patients at risk of toxicity. The physician
will also appreciate comments related to genetic poly-
morphisms, risk for pharmacokinetic interactions in sit-
uations, and pharmacokinetic properties of the drug
when given to elderly patients or patients with hepatic
or renal insufficiency.
In situations where drug concentrations are particularly
low, it is often not clear whether the patient is an UM or
whether he or she is noncompliant in that the drug
intake is irregular.The analysis of a second plasma sam-
ple may help verify compliance but, depending on the
result, a pharmacogenetic test should be carried out.
Clearly a PM (CYP 2D6) status should not automati-
cally result in interruption of a treatment,18,171 but the
dose should be adapted using clinical judgment and
TDM.
Conclusion
TDM is a valuable approach to optimize both short-
term and lifelong treatment of psychiatric patients with
antidepressants,172 and a combination of TDM with phar-
macogenetic tests will be increasingly useful, particularly
because in near future, pharmacogenetic tests regarding
pharmacodynamic parameters will also be clinically rel-
evant.173 Many data on plasma concentrations of psy-
chotropic drugs and the plasma concentration–clinical
effectiveness relationship have accumulated over the
past few years, and encouraged this interdisciplinary col-
laboration of specialists who brought about this consen-
sus on TDM.11 Hopefully, it will help to use TDM opti-
mally from a scientific, clinical, and economic point of
view. ❏
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Las pautas de consenso del grupo de expertos AGNP-TDM: foco en el monitoreo terapéutico
de los antidepresivos
El monitoreo terapéutico de fármacos (TDM), que incluye los antidepresivos entre los psicofármacos, se
ha introducido extensamente para optimizar la farmacoterapia en los pacientes psiquiátricos. El 
grupo interdisciplinario de TDM del Arbeitsgemeinschaft für Neuropsychopharmakologie und
Pharmakopsychiatrie (AGNP) ha trabajado en pautas de consenso con el objetivo de entregar a los psi-
quiatras y a los laboratorios de TDM una herramienta que permita optimizar el empleo del TDM. Se defi-
nieron cinco niveles de recomendación basados en la investigación relacionada con el monitoreo de rutina
de concentraciones plasmáticas de fármacos: (1) altamente recomendado, (2) recomendado, (3) útil, (4)
probablemente útil y (5) no recomendado. Además se presentó una lista de indicaciones que justifican el
uso del TDM, como por ejemplo, el control de la adherencia, la falta de respuesta clínica o los efectos
adversos a dosis recomendadas, las interacciones de fármacos,  los programas de farmacovigilancia, la pre-
sencia de alguna particularidad genética en relación con el metabolismo de los fármacos y los pacientes
infanto-juveniles y ancianos. Para algunos fármacos faltan estudios en rangos terapéuticos. De acuerdo
con estudios farmacocinéticos reportados en la literatura, se presentan los rangos objetivos para con-
centraciones plasmáticas clínicamente relevantes de la mayoría de los fármacos. Para muchos antidepre-
sivos un completo análisis de la literatura de los estudios que abordan la relación concentración plasmá-
tica–eficacia clínica ha permitido la inclusión de rangos terapéuticos de concentraciones plasmáticas.
Además, se han realizado recomendaciones relacionadas con la combinación de pruebas farmacogenéti-
cas (fenotipo o genotipo) con el TDM. Finalmente, se han entregado instrucciones prácticas para los pro-
fesionales de los laboratorios y los psiquiatras tratantes de cómo utilizar el TDM: preparación del TDM,
análisis de fármacos, informe e interpretación de resultados y un adecuado uso de la  información para
el tratamiento del paciente. El TDM es un proceso complejo que requiere de una óptima coordinación
interdisciplinaria de un procedimiento que involucra pacientes, psiquiatras tratantes, farmacólogos clíni-
cos y especialistas en laboratorio clínico. Esta pauta de consenso debiera ser útil para optimizar el TDM
de los antidepresivos.
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Recommandations du groupe d’experts AGNP-TDM: Le monitoring à but thérapeutique des anti-
dépresseurs
Le dosage plasmatique de médicaments psychotropes dans un but thérapeutique (therapeutic drug monito-
ring (TDM)) y compris des antidépresseurs a été largement introduit pour optimiser la pharmacothérapie
de patients psychiatriques. Le groupe interdisciplinaire AGNP-TDM (Arbeitsgemeinschaft für
Neuropsychopharmakologie und Phamakopsychiatrie; Association de Neuro-psycho-pharmacologie et de
Pharmacopsychiatrie) a élaboré des recommandations dans le but de procurer aux psychiatres et aux labora-
toires TDM un outil pour optimiser l’utilisation du TDM. Basés sur des résultats obtenus par la recherche, cinq
niveaux de recommandations ont été définis par rapport au monitoring de routine des taux plasmatiques de
médicaments : 1. fortement recommandé, 2. recommandé, 3. utile, 4. probablement utile, 5. pas recommandé.
De plus une liste d’indications qui justifient l’utilisation des TDM est présentée, par exemple : contrôle de l’ob-
servance, absence de réponse clinique ou effets secondaires à des doses généralement recommandées, inter-
actions médicamenteuses, programme de pharmacovigilance, présence d’une particularité génétique concer-
nant le métabolisme de médicaments, enfants, adolescents et patients âgés. Pour quelques médicaments, des
études sur les marges thérapeutiques manquent, mais des marges cibles pour des concentrations plasmatiques
cliniquement significatives sont présentées pour la plupart des médicaments, basées sur des études phar-
macocinétiques rapportées dans la littérature. Pour beaucoup d’antidépresseurs, une analyse complète de la
littérature sur les études qui traitent de la relation concentration plasmatique – efficacité clinique a permis
de présenter des marges thérapeutiques de concentrations plasmatiques. En outre, des recommandations
sont données par rapport à la combinaison de tests pharmacogénétiques (phénotypage ou génotypage) avec
le TDM. Finalement, des instructions pratiques sont données aux techniciens responsables de laboratoires
et aux médecins traitants qui utilisent le TDM : préparation du TDM, analyses de médicaments, communica-
tion et interprétation du résultat et utilisation adéquate de l’information pour le traitement du patient. Le
TDM est un processus qui nécessite une coordination interdisciplinaire optimale d’une procédure qui implique
des patients, des médecins traitants, des pharmacologues cliniques et des spécialistes du laboratoire clinique.
Ce « Consensus guideline » (recommandations) devrait être utile pour optimiser le TDM d’antidépresseurs.
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